Literature DB >> 1691240

Production of rabbit antibodies against carboxy-terminal epitopes encoded by bullous pemphigoid cDNA.

T Tanaka1, N J Korman, H Shimizu, R A Eady, V Klaus-Kovtun, K Cehrs, J R Stanley.   

Abstract

A partial cDNA clone (called BP cDNA) with coding sequences for the carboxy-terminal region of bullous pemphigoid (BP) antigen has been recently isolated and sequenced. In order to determine whether specific peptides encoded by the cDNA could be used to raise antibodies against BP antigen, fusion proteins derived from fragments of the BP cDNA and 17-mer or 19-mer synthetic peptides, corresponding to its deduced amino acid sequence, were used to generate rabbit antibodies. Three restriction enzyme fragments, 1179 bp (5' end), 264 bp (middle), and 546 bp (3' end), of the 1992 open reading frame (ORF) of BP cDNA were subcloned in frame into pEX plasmids to make beta-galactosidase fusion proteins FP1, FP2, and FP3, respectively. Fusion proteins of the predicted molecular weight, and which bound anti-beta-galactosidase antibodies, were produced, confirming the length of the predicted ORF. Rabbits immunized with FP1, but not FP3, produced antibodies, similar to authentic antibodies from BP patients, which: 1) bound the epidermal basement membrane at titers over 10,000, as determined by indirect immunofluorescence; 2) bound the basement membrane on the roof of 1 M NaCl-split skin; 3) immunoprecipitated the 230-kD BP antigen; and 4) bound the hemidesmosome, as determined by immunoelectron microscopy. Rabbits immunized with FP2 also produced lower titer BP-like antibodies. We further showed that short hydrophilic synthetic peptides, contained in FP1, could induce similar BP-like antibodies in rabbits at immunofluorescence titers up to 2560. These rabbit antibodies should prove useful for further studies on the function and structure of particular epitopes of BP antigen as well as on the pathophysiology of disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691240     DOI: 10.1111/1523-1747.ep12876200

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  23 in total

1.  1-2B7B: monoclonal antibody reacting to the 120 kDa polypeptide component of human epidermal hemidesmosomes.

Authors:  X M Zhang; Y Horiguchi; M Ueda; T Yoshiki; S Imamura
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

2.  Hemidesmosome ontogeny in digit skin of the human fetus.

Authors:  J R McMillan; R A Eady
Journal:  Arch Dermatol Res       Date:  1996-02       Impact factor: 3.017

Review 3.  Mechanisms of Disease: Pemphigus and Bullous Pemphigoid.

Authors:  Christoph M Hammers; John R Stanley
Journal:  Annu Rev Pathol       Date:  2016-02-22       Impact factor: 23.472

4.  A homozygous mutation in the integrin alpha6 gene in junctional epidermolysis bullosa with pyloric atresia.

Authors:  L Ruzzi; L Gagnoux-Palacios; M Pinola; S Belli; G Meneguzzi; M D'Alessio; G Zambruno
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

5.  Human autoantibodies against the 230-kD bullous pemphigoid antigen (BPAG1) bind only to the intracellular domain of the hemidesmosome, whereas those against the 180-kD bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the hemidesmosome in normal human and swine skin.

Authors:  A Ishiko; H Shimizu; A Kikuchi; T Ebihara; T Hashimoto; T Nishikawa
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

6.  The role of complement in experimental bullous pemphigoid.

Authors:  Z Liu; G J Giudice; S J Swartz; J A Fairley; G O Till; J L Troy; L A Diaz
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180.

Authors:  Z Liu; L A Diaz; J L Troy; A F Taylor; D J Emery; J A Fairley; G J Giudice
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

8.  Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes.

Authors:  E Schmidt; B Wehr; E M Tabengwa; S Reimer; E-B Bröcker; D Zillikens
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

9.  Defective expression of plectin/HD1 in epidermolysis bullosa simplex with muscular dystrophy.

Authors:  Y Gache; S Chavanas; J P Lacour; G Wiche; K Owaribe; G Meneguzzi; J P Ortonne
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

Review 10.  Recent advances on the 180-kDa epidermal antigen in autoimmune subepidermal bullous skin diseases.

Authors:  P Bernard
Journal:  Springer Semin Immunopathol       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.